Immunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging viral pandemic in the future. However, therapies that significantly reduce the mortality rate of COVID-19 patients may be a cheaper way compared to vaccines to protect high-risk groups. UK researchers reported on the first therapy in mid-June.
Sotio licences Unum Therapeutics’ CAR-T cell portfolio
Latest NewsPPF-owned company SOTIO has acquired the rights to use the BOXR CAR-T platform and products from Cambridge-based Unum Therapeutics.
Polyphor partners with Fosun Pharma
Latest NewsPolyphor AG has licenced its metastatic cancer drug balixafortide to Fosun Pharma Co Ltd to market the drug exclusively in China.
Immunovia appoints Patrik Dahlen as new CEO
AppointmentsSwedish diagnostic company Immunovia AB announces Patrik Dahlen as new CEO starting November 2020.
Engitix Ltd. lands US$500m deal with Takeda in fibrosis
Latest NewsBritish fibrosis therapeutics start-up Engitix Ltd has entered a collaboration agreement with Takeda to develop anti-fibrotic therapies in liver diseases.
Moderna set to deliver COVID-19 jab to the EU
Latest NewsUS experiemental mRNA vaccine maker Moderna Inc is in advanced talks with the European Commission to supply 80 million doses mRNA-1273, its candidate vs SARS-CoV-2
Scientists map ulcerative colitis
Latest NewsScientists from Leuven, Rotterdam and San Diego have published a sequencing-based map of ulcerative colitis paving the way to new treatments.
COVID-19: Roche and Regeneron join forces
Latest NewsRoche and Regeneron have signed an manufacturing and distribution agreement on Regeneron’s Phase II therapeutic antibody for the treatment of COVID-19.
The role of investors in addressing AMR
OpinionAbigail Herron from Aviva Investors describes why AMR is a blind spot for investors and which action is needed to change it.
Aicuris to launch AiCubator to fight AMR
Latest NewsAntinfectives specialist AiCuris GmbH will launch the AiCubator, a new way to collaborate in anti-infectives and support novel approaches, at the 4th AMR Conference.
Cell-based vaccination vs mortality-reducing therapies
Latest NewsImmunovative Therapies Ltd and its US subsidiary Mirror Biologics Inc. are testing a novel, T cell-based vaccination concept that might protect risk groups from new SARS-CoV-2 variants and any emerging viral pandemic in the future. However, therapies that significantly reduce the mortality rate of COVID-19 patients may be a cheaper way compared to vaccines to protect high-risk groups. UK researchers reported on the first therapy in mid-June.